ImmunityBio heads into October with an unusual split: short conviction remains historically high while the borrow market has quietly eased, creating a setup worth watching ahead of a November earnings date.
The short positioning story is the dominant feature here. Short interest holds at 12.7% of the free float, roughly 125 million shares, a level ORTEX flags as elevated. The ORTEX short score has been running at 83 all week, a reading that places IBRX in the second percentile of the universe on short score rank, meaning almost nobody carries a heavier short-side signal. Days to cover stand at 15.86 per the most recent FINRA fortnightly settlement, which underlines how sticky this short base has become. Yet short interest itself has barely moved, down just 0.05% on the week and 2.5% over the past month, meaning bears are not meaningfully adding or cutting.
Borrow conditions tell a more complicated story, and the contrast matters. Availability has actually been loosening over the past week, rising from a trough near 9% to 17.9% now, still tight but well off the late-August extreme when availability nearly hit zero and every share in the lending pool was out. Cost to borrow has also fallen sharply: down 17% on the week and more than 55% versus a month ago, now at just 1.1%. The mid-September period, when availability repeatedly dipped below 10% and CTB spiked to 1.36%, was more hostile for short sellers. The current reading suggests some pressure has come off the borrow market even as the short score stays near its highs.
Options positioning is measured rather than aggressive. The put/call ratio at 0.38 is only marginally above its 20-day average of 0.37, a z-score of 0.71, well within normal range. The 52-week high on the PCR is 0.42 and the low is 0.20, so current positioning sits in the middle of the band. There is no sign of elevated hedging demand ahead of November 6 earnings. Peers have had a rough week: NTLA fell 5.2%, CRSP dropped 5.1%, and ABSI lost 5.3%, while IBRX itself gave back 4.9%, broadly in line with the gene-editing and small-cap biotech cohort.
The Street view is uniformly bullish but dated. Three covering analysts all rate the stock Buy, with a mean price target of $12.75 against a current price of $8.83, implying roughly 44% upside on paper. The most recent published actions, from HC Wainwright and BTIG in late May and early June, reiterated Buy ratings with targets of $15 and $12 respectively. D. Boral Capital carries an outlier $23 target. No analyst has moved since early June, meaning the consensus has had no material update for four months. The EPS surprise factor score ranks in the 94th percentile, suggesting the company has a strong track record of beating expectations, but near-term EPS momentum scores of 8 (30-day) and 21 (90-day) flag that forward estimate revisions have been moving in the wrong direction recently.
Ownership is heavily concentrated. Patrick Soon-Shiong has a filed Schedule 13D, making him a disclosed activist-class holder, and between his personal holdings and affiliated vehicles including California Capital Equity and NantWorks, the founder controls well over 60% of the company on the most recent 13D/A filed in August. BlackRock and State Street both added shares in the period ending August 31, adding roughly 7.7 million and 3.7 million shares respectively. Insider activity in the available window shows directors exercising options and selling under pre-arranged 10b5-1 plans in late June and early July: the net 90-day insider position is a sale of approximately 435,000 shares worth around $3.9 million, though the 10b5-1 structure reduces the informational weight of those moves considerably.
The next earnings event on November 6 is 37 days away. The four most recent post-earnings moves were plus 2.3%, plus 1.4%, minus 2.6%, and plus 4.5% on the day, suggesting the stock tends to react modestly to prints in both directions. With the borrow market loosening but short score near its highs, the question heading into that event is whether the current stability in short interest reflects a settled bearish conviction or a population of shorts watching for a catalyst to move.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
